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ABSTRACT Enterohemorrhagic Escherichia coli (EHEC) and enteropathogenic E. coli
(EPEC) are enteric bacterial pathogens of worldwide importance. Most EPEC and
non-O157 EHEC strains express lymphostatin (also known as LifA), a chromosomally
encoded 365-kDa protein. We previously demonstrated that lymphostatin is a puta-
tive glycosyltransferase that is important in intestinal colonization of cattle by EHEC
serogroup O5, O111, and O26 strains. However, the nature and consequences of the
interaction between lymphostatin and immune cells from the bovine host are ill de-
ﬁned. Using puriﬁed recombinant protein, we demonstrated that lymphostatin inhib-
its mitogen-activated proliferation of bovine T cells and, to a lesser extent, prolifera-
tion of cytokine-stimulated B cells, but not NK cells. It broadly affected the T cell
compartment, inhibiting all cell subsets (CD4, CD8, WC-1, and  T cell receptor [-
TCR]) and cytokines examined (interleukin 2 [IL-2], IL-4, IL-10, IL-17A, and gamma in-
terferon [IFN-]) and rendered T cells refractory to mitogen for a least 18 h after
transient exposure. Lymphostatin was also able to inhibit proliferation of T cells
stimulated by IL-2 and by antigen presentation using a Theileria-transformed cell line
and autologous T cells from Theileria-infected cattle. We conclude that lymphostatin
is likely to act early in T cell activation, as stimulation of T cells with concanavalin A,
but not phorbol 12-myristate 13-acetate combined with ionomycin, was inhibited.
Finally, a homologue of lymphostatin from E. coli O157:H7 (ToxB; L7095) was also
found to possess comparable inhibitory activity against T cells, indicating a poten-
tially conserved strategy for interference in adaptive responses by attaching and ef-
facing E. coli.
KEYWORDS lymphostatin, lymphocyte, inhibition, adaptive, immunity, Escherichia
coli, cell proliferation, host-pathogen interactions, adaptive immunity, inhibition,
lymphocytes
Enterohemorrhagic Escherichia coli (EHEC) is associated with hemorrhagic colitis andhemolytic-uremic syndrome in humans, and cattle are a key reservoir of infection.
Enteropathogenic E. coli (EPEC) shares many features with EHEC and is a major cause
of acute diarrhea in infants in developing countries. Both pathotypes colonize intestinal
mucosa via the formation of attaching and effacing (AE) lesions in a manner that
requires a type III protein secretion system (T3SS), as well as accessory virulence factors
(1). One such factor is lymphostatin (also known as LifA), a chromosomally encoded
protein with a predicted molecular mass of 365 kDa that is expressed by most EPEC and
non-O157 EHEC strains (2). Lymphostatin was ﬁrst described for EPEC O127:H6 as a
factor required for inhibition of mitogen-activated proliferation of human peripheral
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blood monocytes (PBMCs) (2), an activity that had also been observed with murine
splenic and mucosal lymphocytes treated with EPEC lysates (3). Lymphostatin was
recently reported to be a secreted effector of the T3SS (4); however, lymphostatin
activity does not require injection of the protein into cells, as it can be demonstrated
with a T3SS-negative E. coli K-12 strain bearing lifA on a cosmid (2) and detected using
puriﬁed protein (5). Separately, a factor nearly identical to LifA was reported to mediate
adherence of EHEC O111:H to cultured epithelial cells (EHEC factor for adherence
[Efa1]) (6), and mutations in the gene impaired type III secretion in some strains (7, 8).
We previously demonstrated that lymphostatin is required for intestinal colonization of
calves by non-O157 EHEC serogroups O5, O111 (7), and O26 (8); however, the extent to
which this reﬂects a role in modulation of bovine immune responses, adherence, or
indirect effects on type III secretion remains ill deﬁned. Lymphostatin has also been
shown to promote colonization of the murine intestines and colonic hyperplasia by the
attaching and effacing pathogen Citrobacter rodentium (9).
Lymphostatin exhibits N-terminal homology with large clostridial toxins, including a
conserved glycosyltransferase domain and predicted DXD catalytic motif (6). Progress
in understanding the mode of action of the protein was previously hindered by the
instability of plasmid clones and suspected protein toxicity; however, we recently
developed an inducible system for afﬁnity puriﬁcation of LifA (5). Using site-directed
mutagenesis, we observed that the DXD motif is required for lymphostatin activity and
for binding of UDP-N-acetylglucosamine (UDP-GlcNAc), indicating that it may act by
GlcNAc modiﬁcation of cellular factors. The EHEC O157:H7 serotype that is predomi-
nantly associated with human disease in North America and Europe typically lacks
lymphostatin; however, sequencing of the prototype strain revealed that a homologue
is encoded on the pO157 virulence plasmid (toxB or l7095 [10]) that has subsequently
been found in many EHEC and EPEC strains (11–13) and proposed to be type III secreted
(4). ToxB exhibits 29.2% identity (and 62.3% similarity [14]) at the amino acid level to
LifA using the full amino acid sequence, and a closer examination of the ﬁrst 1,033
amino acids (aa) (encompassing the glycosyltransferase domain) shows a higher iden-
tity, 36.4% (and 68.7% similarity). It was reported that E. coli O157:H7 has a
lymphostatin-like activity that was absent upon curing of the ca. 92-kb pO157 plasmid
(2). However, plasmid pO157 encodes other putative virulence factors, and a signiﬁcant
role for toxB in inhibition of lymphocyte proliferation could not be detected with a toxB
deletion mutant, albeit using an insensitive assay reliant on crude bacterial lysates (15).
Certain Chlamydia species also contain a family of lymphostatin homologues which
have been implied to act as cytotoxins (16).
Lymphostatin activity does not appear to be host restricted, having been detected
with mitogen-activated peripheral blood monocytes from humans (2), mice (9), and
calves (7). However, relatively little is known about whether it acts on speciﬁc cell
subsets and the sensitivity of the effect to stimulus (e.g., mitogens, antigens, or
cytokines). This is particularly pertinent in relation to colonization of the bovine
reservoir host, where modulation of innate and adaptive responses is likely to play a
role in bacterial persistence. We therefore investigated the activity of recombinant LifA
against bovine T, B, and NK cells and lymphocyte subsets stimulated with various
agonists. We suggest that lymphostatin acts as a global T cell inhibitor, possibly by
conditioning T cells to be functionally unresponsive, as treated cells remain refractory
to mitogen for many hours after transient exposure. We also observed that lymphos-
tatin blocks mitogen-activated secretion of cytokines and, for the ﬁrst time, stimulation
induced by antigen presentation to autologous lymphocytes. We successfully cloned,
expressed, and afﬁnity puriﬁed full-length ToxB from E. coli O157:H7 and deﬁnitively
showed that it possesses lymphostatin-like activity. This suggests a potentially con-
served strategy among AE E. coli to interfere with adaptive immune response and adds
to the relatively small number of bacterial factors described to directly target adaptive
immune function.
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RESULTS
Full-length lymphostatin is a selective inhibitor of T and B lymphocyte activa-
tion. Recently, we showed that recombinant full-length lymphostatin was able to
potently inhibit mitogen-stimulated T cell proliferation, with a 50% effective dose
(ED50) in the femtomolar range in the absence of direct cytotoxic effects (5). Given that
all previous examination of the effect of lymphostatin has been in bulk PMBC prepa-
rations using predominantly T cell-affecting mitogens, we wished to determine
whether the effect of lymphostatin is restricted to T cells or whether other lymphocytes
might also be affected. To that end, we compared the effects of lymphostatin on
stimulation of T cells, B cells, and NK cells. Data obtained for T cells were essentially as
reported previously, with a clear sigmoidal dose-response curve and an ED50 of 54
pg/ml (19 pg/ml) (Fig. 1A). Incubation of B cells with lymphostatin, followed by
stimulation by interleukin 4 (IL-4), an activator of B cell proliferation, showed that
lymphostatin induced a reduction in the proliferative capacity of B cells compared to
that of the control (Fig. 1B; black circles indicate treatment with lymphostatin, and black
squares indicate treatment with a similar concentration of lymphostatin protein buffer).
The effect was concentration dependent and was titrated out by 1 ng/ml (Fig. 1B). The
ED50 of recombinant LifA (rLifA) on B cells was calculated to be 11 ng/ml (14 ng/ml;
30 pM), about 200-fold lower than the ED50 for T cells. In contrast, lymphostatin had
little or no effect on the production of gamma interferon (IFN-) by NK cells stimulated
with IL-12 and IL-18 (Fig. 1C). IL-12 and IL-18 are able to potently induce NK cells to
produce high levels of IFN-. Although the IFN- production was lower in the presence
of rLifA or carrier than that of IL-12 or IL-18 alone (Fig. 1C, single gray circle), no
signiﬁcant differences were detected.
Effect of lymphostatin on bovine T cell subsets and cytokine production.
Having established that the effect of lymphostatin is most potent on T lymphocytes, we
sought to understand whether it has a global effect across the T cell compartment, or
if it preferentially affects a speciﬁc subset of T cells. First, the percentage of cells
expressing CD4, CD8, WC-1 (a coreceptor of  T cell receptor [-TCR]), and -TCR
was assessed by ﬂow cytometry, using an enriched T cell preparation treated with a
subsaturating concentration of rLifA (approximately the ED50) and concurrent stimu-
lation with concanavalin A (ConA). These cells reﬂect the main T lymphocyte subsets
present in bovine peripheral blood. In comparison to the controls treated with ConA
alone, there was no statistically signiﬁcant change in the proportions of any of the T cell
populations tested (paired t test; P values  0.05 [Fig. 2]). To further probe this effect,
we quantiﬁed the secretion of a number of T cell-derived cytokines in response to ConA
FIG 1 Effect of recombinant lymphostatin on proliferation of primary bovine T, B, and NK cells. (A) Primary T cells
were stimulated with ConA for 72 h, and proliferation was measured using a colorimetric assay. Data are averages 
standard deviations from 8 donors. The ED50 was 54 pg/ml (19 pg/ml) (138 fM). The purity of the population was
85% by ﬂow cytometry. The ConA response was unaffected by treatment with protein carrier buffer (solid
square). (B) Primary B cells were stimulated with recombinant IL-4, and lymphostatin where indicated, for 72 h and
proliferation measured using a colorimetric assay. Data are averages  standard deviations from 4 independent
donors. The ED50 was 11 ng/ml (14 ng/ml) (30 pM).The purity of the population was 97% by ﬂow cytometry.
(C) Primary NK cells were stimulated with recombinant IL-12 and IL-18 overnight. The purity of the cell population
was 85%. Production of IFN- was measured in a sandwich ELISA against a recombinant protein standard. The
amount of IFN- produced by treatment with IL-12 and IL-18 alone is shown as a single data point to indicate the
maximum IFN- release possible. The limit of detection was 2 ng/ml. Data are averages standard deviations from
3 independent donors. Data are plotted with a log scale on the x axis for all charts.
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stimulation of an enriched T cell population that can broadly be used to reﬂect Th1,
Th2, regulatory T cell (Treg), and Th17 subset populations. ConA-stimulated lympho-
cytes (not treated with lymphostatin) secreted IL-2 (703  149 pg/ml), IL-4 (69  45
pg/ml), IL-10 (13.7  4.8 biological units [BU]/ml), IFN- (5  3 ng/ml), and IL-17A (3 
1 ng/ml) above the level of detection in all cases (Fig. 3, solid black squares). Secretion
of all of the cytokines measured showed a dose-dependent decrease in response to
increasing concentrations of lymphostatin, mirroring the proliferation data previously
measured (Fig. 3). In most cases, cytokine secretion was below or close to the limit of
detection by the methods used following treatment with rLifA at 1 ng/ml or higher.
Pretreatment of T cells with lymphostatin induces long-lived resistance to
mitogenic activation. In the assays reported so far, lymphostatin was present in the
medium for the duration of culture. To determine if transient exposure of lymphocytes
to lymphostatin was sufﬁcient to render them refractory to mitogenic stimulation, we
pretreated T cells with a range of protein concentrations (100 ng/ml to 0.1 pg/ml for 1
h) and then washed the cells to remove the protein and added ConA immediately or
1, 3, or 18 h after withdrawal of rLifA. In all cases, concentration-dependent inhibition
of lymphocyte proliferation was observed after transient pretreatment of cells (Fig. 4).
Even 18 h after withdrawal of lymphostatin at doses of 1 ng/ml or higher, the T cells
were inhibited from proliferating in the presence of ConA.
Lymphostatin inhibits lymphocyte stimulation via antigen presentation. In
order to establish whether the effect of lymphostatin on lymphocyte proliferation is
speciﬁc to inhibition of mitogenic stimulation, we evaluated the ability of lymphostatin
to inhibit antigen-stimulated activation of bovine CD4 and CD8 T cells. We exploited an
established assay in which antigen-presenting cells (APCs) sustained in culture and
permanently infected with the protozoan parasite Theileria parva were used to present
antigens in vitro to autologous T. parva-speciﬁc T cell populations from cattle that had
been rendered immune to T. parva by simultaneous infection and treatment (a method
for vaccination against the parasite [17, 18]). Activation of the T cells in response to
recognition of antigens presented by the T. parva-infected cells in culture was quan-
tiﬁed by their ability to secrete IFN- using an enzyme-linked immunosorbent spot
(ELISPOT) assay. As in earlier assays, T. parva-speciﬁc T cells and infected cells present-
ing T. parva antigens were incubated with a range of concentrations of lymphostatin or
the carrier control (Fig. 5). For both CD4 cells and CD8 cells, a lymphostatin
concentration-dependent inhibition of the number of IFN--producing cells was mea-
sured by ELISPOT assay compared to that in an untreated control (which indicates the
maximum number of affected cells expected in the assay). The effect with CD4 cells
FIG 2 Effect of subsaturating concentrations of lymphostatin on the abundance of T cell subsets after
ConA-stimulated proliferation. Cells were treated with either ConA with protein carrier buffer or ConA
plus 50 pg/ml of rLifA at a concentration similar to the ED50 for lymphostatin in ConA-stimulated
proliferation. Cells were harvested at 72 h, stained for the indicated surface markers, and measured by
ﬂow cytometry. The averages  standard deviations from four independent donors are shown. There
were no statistically signiﬁcant differences for any of the markers tested between the groups treated with
ConA and ConA plus rLifA for any of the markers tested (paired t test, P  0.05).
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was very clear and showed a similar titration to inhibition of ConA-mediated stimula-
tion, with both the 10-ng/ml and 1-g/ml treatments being statistically signiﬁcantly
different from the carrier control (P 0.05). The effect with CD8 cells was similar; however,
the number of IFN--producing cells was lower, and the variation between experiments
was higher, meaning that the difference did not reach statistical signiﬁcance (P  0.1).
Nonetheless, the trend within each individual replicate mirrors the results obtained with the
FIG 3 Cytokine secretion from bovine T cells treated with lymphostatin and stimulated with ConA. Cytokine
secretion was measured at 24 h poststimulation in cell culture supernatants using quantitative sandwich ELISAs.
The averages  standard deviations from 3 independent donors are shown. Data from samples treated with
lymphostatin are indicated by solid circles. Themaximum secretion expected is from cells treated with ConA and
protein carrier buffer (but no lymphostatin). The values obtained for these samples are indicated by a solid
square over the 100 ng/ml marker and are stated in Results. The ED50 required to inhibit cytokine production
was not signiﬁcantly different from the ED50 required to inhibit lymphocyte proliferation in all instances
examined (one-way analysis of variance [ANOVA] and post hoc Tukey test, P  0.05). The limits of detection for
each ELISA were as follows: IL-2, 40 pg/ml; IL-4, 4 pg/ml; IL-10, 2 BU/ml; IFN-, 2 ng/ml; and IL-17A, 188 pg/ml.
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CD4 cells, with lymphostatin inhibiting antigen-induced IFN- secretion by bovine CD4
and, likely, CD8 T cells, which is consistent with the data obtained for T cell subsets and
cytokine production in mitogen-stimulated T cell populations.
IL-2-induced expansion of T cells can be inhibited by lymphostatin. Given that
IL-2 is the major growth factor for induction of activation and expansion of the T cell
compartment, we examined whether lymphostatin was able to interfere directly in IL-2
signaling during the assays, or whether its effects are restricted to the initiation of
proliferation. T cells were treated with a range of lymphostatin concentrations and
driven to proliferate with IL-2. Clear concentration-dependent inhibition of IL-2-
stimulated proliferation of bovine T cells was observed (Fig. 6), with an ED50 calculated
to be 500 pg/ml (290 ng/ml) (1.4 pM).
PMA and ionomycin stimulation of T cells is not affected by lymphostatin. In
order to investigate the stage at which lymphostatin affects T cell signaling and
FIG 5 Effect of lymphostatin on stimulation via antigen presentation to deﬁned bovine T cells. Data from 4
independent experiments, each with technical replication in triplicate, are shown for both CD4 and CD8 T cells.
Each symbol refers to the mean of an individual experiment, with the overall mean indicated by the solid black bar.
“Control” refers to antigen stimulation of the T cells where protein carrier buffer was included but not protein (this
is the maximum number of cells that would be expected to be measured in the assay). A minimum spot size of 15
and intensity of 5 were used for analysis. *, P  0.05; §, P  0.1 (compared to carrier control; paired t test).
FIG 4 Transient pretreatment of primary bovine T cells with lymphostatin induces lasting inhibition of
the response to ConA. Primary T cells were pretreated with rLifA, protein was washed away, and cells
were stimulated with 1 g/ml of ConA at the times indicated. Proliferation was measured by colorimetric
assay. Data represent averages  standard deviations from 4 independent donors. Data are plotted with
a log scale on the x axis.
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disrupts the proliferative program, we queried whether rLifA was able to inhibit
proliferation stimulated using phorbol 12-myristate 13-acetate (PMA) and ionomycin.
PMA activates protein kinase C, while ionomycin is a calcium ionophore. Together they
mimic TCR and coreceptor activation, but in a way that bypasses membrane receptor
signaling (19). Lymphostatin was not able to inhibit PMA- and ionomycin-induced T cell
proliferation (Fig. 7), in contrast to controls stimulated with ConA, which were signiﬁ-
cantly impaired in proliferation at 1 ng/ml and 100 ng/ml of rLifA (P  0.05), indicating
that lymphostatin may interfere with membrane-proximal signaling or pathways de-
pendent on such.
The lymphostatin homologue ToxB from E. coli O157:H7 also inhibits ConA-
stimulated T cell proliferation. While it is clear that lymphostatin is a potent inhibitor
FIG 6 Effect of lymphostatin on IL-2-stimulated proliferation of primary bovine T cells. PBMCs were
initially stimulated with ConA. After 4 days, cells were treated with rLifA at the ﬁnal concentrations
indicated, followed immediately by stimulation with IL-2 for a total of 72 h. Proliferation was measured
using a colorimetric assay. ED50  500 pg/ml ( 290 ng/ml) (1.4 pM). Data from 4 independent donors
are shown. Cells with no stimulus, cells stimulated with IL-2 but no protein, and cells treated with protein
carrier buffer and stimulated with IL-2 were included as controls. The IL-2 response is unaffected by
protein carrier buffer (solid square). Data are plotted with a log scale on the x axis.
FIG 7 Effect of lymphostatin on PMA- and ionomycin (Iono)-stimulated proliferation of primary bovine
T cells. Primary T cells were treated with rLifA at the ﬁnal concentrations indicated and stimulated with
50 ng/ml of PMA and 1 g/ml of ionomycin for 72 h. Proliferation was measured using a colorimetric
assay. Averages  standard deviations from 3 independent donors are shown. Data are plotted with a
log scale on the x axis. The difference in ConA and PMA and ionomycin responses was signiﬁcant at two
rLifA concentrations (*, P  0.05 at 1 and 100 ng/ml comparing PMA and Iono to ConA). Cells without
treatment, cells treated with ConA or PMA and ionomycin, and cells treated with protein carrier buffer
and ConA or PMA and ionomycin were included as controls.
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of bovine lymphocyte function and a key colonization factor of serogroup O5, O26, and
O111 strains in calves (7, 8), it is absent from most serogroup O157 strains, which are
prevalent in ruminants in many parts of the world and an important cause of zoonotic
diarrheal illness in humans. A homologous protein (ToxB) is encoded by most EHEC
O157 strains, but deﬁnitive evidence of a role in modulating lymphocyte function is
lacking. We cloned the full-length ToxB protein in a tightly inducible prokaryotic
expression system, afﬁnity puriﬁed the protein to ca. 90% purity (Fig. 8, inset) and
evaluated its ability to inhibit ConA-stimulated proliferation of bovine T cells relative to
rLifA. Recombinant ToxB inhibited ConA-stimulated proliferation of bovine T cells in a
concentration-dependent manner (Fig. 8), with an ED50 of 1,100 pg/ml (880 pg/ml)
(2.8 pM) for ToxB, compared to 10 pg/ml (10 pg/ml) (0.03 pM) for rLifA. This
represents about a 100-fold difference in ED50; however, ToxB was still able to inhibit
proliferation of T cells in the picomolar range of concentrations.
DISCUSSION
Lymphostatin plays an important role in intestinal colonization of calves by non-
O157 EHEC (7) and in persistence of C. rodentium in murine intestines and induction of
colonic hyperplasia (9). It has been hypothesized that this may reﬂect its ability to
interfere with lymphocyte proliferation and proinﬂammatory cytokine synthesis. Previ-
ous studies have mostly utilized crude peripheral blood monocyte populations to
demonstrate LifA activity (2, 7, 8, 20, 21), and the extent to which lymphostatin acts on
speciﬁc cell populations and can inhibit stimulation via distinct agonists and pathways
has received little attention. Moreover, published assays have relied on crude lysates of
E. coli producing lymphostatin, in which activity can be hard to separate from the
inhibitory effects of other constituents. Indeed, inhibitory effects of lysates of non-
pathogenic E. coli strains lacking LifA have been detected on human or bovine PBMCs
when used at higher concentrations (2, 8).
In this study, using cells from the bovine reservoir of EHEC, we demonstrated that
highly puriﬁed lymphostatin predominantly acts on the T cell compartment, with near
complete inhibition of proliferation of all major T cell subsets in the femtomolar range.
As previously reported, no evidence that lymphostatin is directly cytotoxic to target
FIG 8 Effect of recombinant ToxB on mitogenic stimulation of primary bovine T cells. Primary T cells were
treated with either recombinant ToxB or LifA, followed by immediate addition of ConA for a total of 72
h, and proliferation was measured using a colorimetric assay. The ED50 was calculated to be 1.1 ng/ml
(0.88 ng/ml) (2.8 pM) for ToxB, compared to 0.013 ng/ml (0.01 ng/ml) (0.03 pM) for LifA. Averages 
standard deviations from 4 independent donors are shown. Data are plotted with a log scale on the x
axis. (Inset) L, LifA; T, ToxB. In a comparison of the effect of ToxB to that of LifA, the ED50 is not statistically
signiﬁcantly different. Cells without treatment, cells treated with ConA, and cells treated with protein
carrier buffer and ConA were included as controls.
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cells exists (5). The observed inhibition of cytokine production by LifA-treated bovine T
cells is consistent with previously published data (2) showing that expression of IL-2,
IL-4, and IFN- was reduced by treatment of ConA-stimulated human PBMCs with
lymphostatin. The latter study differed by measuring cytokine mRNA levels rather than
secreted proteins, and IL-10 and IL-17 were not assessed. From these results, we would
conclude that it seems likely that lymphostatin has a global effect on the T cell
compartment, without bias for a particular cell subset or type of response (i.e., Th1
versus Th2), at least under the conditions tested in this study. It would be of interest to
conﬁrm this hypothesis in vivo; however, analysis of immune responses induced by lifA
mutants is likely to be confounded by the attenuating effect of the mutation, such that
cytokine responses are likely to be affected by both the presence of lymphostatin and
the bacterial load acting on the immune system. As lifA is required for intestinal
colonization of mice by C. rodentium, it would be of interest to determine if the role of
lymphostatin in bacterial persistence is still observed when lymphocyte subsets are
removed by mutagenesis or antibody-mediated depletion.
Lymphostatin also inhibited IL-4-mediated activation of bovine B cells, but to a
lesser extent than with ConA-treated T cells, with higher LifA concentrations being
required to detect equivalent inhibition. Bovine NK cells were insensitive to lymphos-
tatin, at least in the context of IFN- induction under the assay conditions. The basis of
cell-type-speciﬁc responses to LifA requires further study and may reﬂect differences in
receptor availability and/or the pathways or molecules on which lymphostatin acts. It
will also be of interest to explore if lymphostatin differentially affects activated and
differentiated subsets of lymphocytes, although such populations can be difﬁcult to
consistently establish in vitro.
For the ﬁrst time, we have demonstrated that lymphostatin is able to inhibit
antigen-stimulated proliferation of bovine CD4 T cells. This is signiﬁcant in the context
of natural infections, and future experiments could consider if adaptive immune
responses of cattle to EHEC-expressed antigen(s) are sensitive to the presence or
absence of lymphostatin. However, as noted above, this is complicated by the fact that
lymphostatin inﬂuences intestinal colonization by EHEC, and thus, total exposure to
antigens can be expected to be lower upon infection with lifA mutants relative to the
wild-type strain. We previously examined the phenotype of intraepithelial lymphocytes
(IEL) exposed to Shiga toxin-producing E. coli O103 in situ in a bovine ligated intestinal
loop model in which equivalent densities of wild-type and mutant bacteria can be
instilled into segments of the gut (22). No signiﬁcant effects on proliferative capacity,
NK cell activity, or cytokine transcript proﬁle were detected on exposure to EHEC in
these studies (22). The strain used was positive for the lifA gene by PCR, but it is
unknown whether the full-length protein was expressed under the assay conditions,
and truncated variants of lifA exist in some AE E. coli organisms. It is noteworthy that
attenuation of lifA mutants of EHEC in calves or C. rodentium in mice can be detected
before adaptive responses may be expected to have developed. Further, a DXD
substitution that ablated lymophostatin activity against bovine PBMCs (8) and T cells (5)
did not signiﬁcantly attenuate an EHEC O26:H strain in a calf intestinal colonization
model, indicating that the immunomodulatory role of LifA may not be strictly necessary
for persistence of EHEC in cattle (8), though it should be stressed that adaptive immune
responses and long-term persistence were not investigated in this study. It is possible
that the attenuation of lifAmutants reﬂects the additional putative role of lymphostatin
as an adhesin and/or indirect effects on the expression and secretion of type III secreted
proteins as has been observed in some strains. Moreover, recent evidence indicates that
LifA is itself an effector of the T3SS, and its role(s) once injected into cells is not fully
understood. The availability of highly puriﬁed lymphostatin offers scope to revisit
activity of the protein against constituents of the mucosal immune system and devel-
opment of adaptive immune responses to pathotypes of E. coli in situ.
The inhibitory effect of lymphostatin on T cells was observed when cells were
stimulated via the IL-2 receptor with soluble IL-2, or with the mitogens ConA or
pokeweed mitogen (20), but not following stimulation with PMA and ionomycin. Given
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that PMA and ionomycin stimulation bypasses membrane receptor signaling, this
implies that lymphostatin likely perturbs the activity of a molecule(s) important in early
signaling events. Given the intricacy and complex interconnections between signaling
pathways in T cell activation, it is difﬁcult to speculate on the level at which lymphos-
tatin exerts its activity. However, the fact that lymphostatin inhibits ConA stimulation,
as well as IL-2-stimulated proliferation, but not PMA and ionomycin makes the
membrane-proximal signaling events that feed into the mitogen-activated protein
kinase (MAPK) pathway attractive targets for further investigation. The murine model of
C. rodentium colonization (9) and published sensitivity of murine lymphocytes to LifA
(9) offer opportunities to examine the role of lymphostatin when speciﬁc signaling
pathways are ablated via gene knockouts or inhibitors.
Our recent ﬁnding that lymphostatin binds UDP-GlcNAc in a manner that requires
a DXD motif that is also required for inhibitory activity (5) supports predictions from
sequence homology and structural modeling that lymphostatin acts as a glycosyltrans-
ferase. It is noteworthy that our study found that T cells are rendered refractory to
mitogen for at least 18 h after transient exposure to lymphostatin, indicating that LifA
may rapidly act on T cells and that any modiﬁcation(s) has a lasting effect. Studies on
the binding of LifA to lymphocytes, whether uptake occurs via speciﬁc pathways, and
whether LifA requires processing in order to act on its cellular target are warranted and
may help to explain differences in cell sensitivity. Indeed, it is noteworthy that lym-
phostatin is predicted to contain a cysteine protease motif, which in the case of large
clostridial toxins is required for autocatalytic cleavage of the toxin following its inser-
tion in the endosome membrane in order to release the catalytic domain into the
cytosol. Our current research aims to identify cellular proteins that interact with
lymphostatin and whether they act as GlcNAc acceptors.
It is striking that despite the role of lymphostatin in intestinal colonization by various
attaching and effacing pathogens, it is absent in the vast majority of serogroup O157
strains that are prevalent in Europe and America. A homologue encoded by the pO157
virulence plasmid was proposed to be functionally equivalent to LifA based on loss of
lymphostatin-like activity against ConA-stimulated human PBMCs upon curing of
pO157 (2). However, pO157 encodes other secreted factors with the potential to
modulate lymphocyte viability or function, including enterohemolysin, the StcE met-
alloprotease, and EspP serine protease (23). Deletion of toxB did not appear to affect
intestinal colonization of calves by E. coli O157:H7, despite pleotropic effects on the
expression and secretion of type III secreted proteins (23, 24). Moreover, although
lysates of E. coli O157:H7 were found to inhibit mitogen-activated proliferation of
bovine PBMCs, deletion of toxB did not fully alleviate this inhibition (15), at least within
the limits of the sensitivity of an assay that relied on crude lysates. Here, were
deﬁnitively show that highly puriﬁed recombinant ToxB is a ca. 365-kDa protein
capable of concentration-dependent inhibition of ConA-stimulated proliferation of
bovine T cells. The ED50 for ToxB was calculated to be about 100-fold lower than that
seen for lymphostatin tested in parallel, but inhibition was nevertheless detected in the
picomolar range, without an apparent cytotoxic effect. The data indicate that LifA and
ToxB are part of a family of lymphocyte-inhibitory factors, and further studies are now
needed to determine if they act on conserved pathways via shared glycosyltransferase
activity. Indeed, a further allelic variant of toxB has been described (toxB2, distinct from
the toxB1 allele found in serogroup O157 strains [11]), and it will be of interest to
determine if such variants share activity and a common mode of action.
Extensive literature has emerged regarding the strategies used by attaching and
effacing E. coli to modulate innate immunity, in particular via the activity of type III
secreted effectors (25). However, it is becoming clear that AE E. coli also speciﬁcally targets
the adaptive response. Recently, it was shown that EHEC selectively depletes CD8 T cells
in cattle in a manner that requires the locus of enterocyte effacement (26), and the data
presented here suggest that lymphostatin and ToxB may act in concert with this strategy
to dampen global T cell responses by conditioning T cells to be insensitive to stimuli, likely
by modifying cellular factors through glycosyltransferase activity.
Cassady-Cain et al. Infection and Immunity
February 2017 Volume 85 Issue 2 e00845-16 iai.asm.org 10
 o
n
 February 3, 2017 by guest
http://iai.asm
.org/
D
ow
nloaded from
 
MATERIALS AND METHODS
Antibodies. The majority of antibodies used in this study are commercially available or previously
described as shown in Table 1.
Expression plasmids and cloning. The pRham-LifA-6xH plasmid, encoding lifA from the prototype
EPEC O127:H6 strain E2348/69 under the control of a rhamnose-inducible glucose-repressible promoter,
has been described previously (5). The full-length gene encoding ToxB (approximately 9.5 kb) was cloned
using the same commercially available Expresso rhamnose cloning and expression system (Lucigen Inc.).
The ToxB gene was ampliﬁed using genomic DNA from E. coli O157:H7 strain TUV 93-0 (an stx1 and stx2
mutant of the prototype EDL933 strain [27]) as a template. Amplicons were generated using the primers
ToxB-pRham For (5= GAA GGA GAT ATA CAT ATG ATT CAT CCT GGC TCT TCT TTA 3=) and ToxB-pRham Rev
(5=-GTG ATG GTG GTG ATG ATG CTT TTT TGA GGG GAC AAT 3=). Clones were veriﬁed as previously described
using Sanger sequencing on both strands and alignment of reads to the EDL933 toxB (l7095) sequence (5).
Recombinant protein production and puriﬁcation. Recombinant His-tagged lymphostatin (rLifA)
was overexpressed in E. cloni cells (Lucigen Inc.) cultured in lysogeny broth at 30°C with shaking at 250
rpm to an absorbance at 600 nm (A600) of 0.8, induced and puriﬁed as previously described (5).
Recombinant ToxB (rToxB) was overexpressed in E. cloni cells cultured in 2	 tryptone yeast (TY) broth.
Cells were initially grown at 37°C and 250 rpm to an A600 of0.4 and cooled to 20°C, and expression was
induced by the addition of 0.2% (wt/vol) L-rhamnose once the A600 reached 0.7. Cells were cultured for
a further 20 h at 20°C and harvested by centrifugation. Cell pellets were resuspended in 20 mM sodium
phosphate (pH 7.5), 300 mM sodium chloride, 500 mM NDSB201, 10% (vol/vol) glycerol, 1 mM dithio-
threitol (DTT), 100 M phenylmethylsulfonyl ﬂuoride, 1 protease inhibitor tablet/3 g of cells (cOmplete,
EDTA free; Roche), and 0.2% (vol/vol) Tween 20 and lysed by a single passage at 30 kpsi through a
Constant Systems Cell Disruptor TS series benchtop instrument at 6°C (Constant Systems). All puriﬁcation
steps were carried out on ÄKTAexplorer 10 (GE Healthcare) equipment at 6°C. Cell lysates were clariﬁed
by centrifugation and puriﬁed using a Co2 ion-metal afﬁnity chromatography (HisTrap FF Crude 5 ml;
GE) column, preequilibrated in buffer A (20 mM sodium phosphate [pH 7.5], 300 mM sodium chloride,
10% [vol/vol] glycerol, 1 mM DTT, 0.2% [vol/vol] Tween 20). rToxB was eluted by increasing the
concentration of buffer B (20 mM sodium phosphate [pH 7.5], 300 mM sodium chloride, 250 mM
imidazole, 10% [vol/vol] glycerol, 1 mM DTT, 0.2% [vol/vol] Tween 20) over a 10-column volume (CV)
linear gradient from 0 to 100%. Fractions containing rToxB were buffer exchanged into 10 mM Tris (pH
7.5), 50 mM sodium chloride, 10% (vol/vol) glycerol, 1 mM DTT, and 0.2% (vol/vol) Tween 20 (buffer C)
and further puriﬁed by strong anion-exchange chromatography (IEX) (HiPrep desalt 26/10; RESOURCE Q
6 ml; GE). The protein was eluted by increasing the concentration of buffer D (10 mM Tris [pH 7.5], 1 M
sodium chloride, 10% [vol/vol] glycerol, 1 mM DTT, 0.2% [vol/vol] Tween 20) over a 20-CV linear gradient
from 0 to 50%. rToxB was eluted at a concentration of 190 mM sodium chloride. The sample was
concentrated to 5 mg/ml of total protein (vivaspin20; 30-kDa molecular mass cutoff; 4,000 	 g;
Sartorius) and passed over a size exclusion column at 1 ml/min preequilibrated in buffer E (20 mM Tris
[pH 7.5], 200 mM sodium chloride, 10% [vol/vol] glycerol, 1 mM DTT, 0.2% [vol/vol] Tween 20) to separate
low-molecular-weight contaminants (Superose-6pg XK16/60; GE). As a ﬁnal polishing and concentration
step, the fractions containing rToxB were bound to a high-performance strong IEX column (Mono Q 5/50
GL; GE), after exchange into buffer C as previously described, and eluted over a 20-CV linear gradient, 0
to 50% buffer D. The protein was eluted at a salt concentration of 230 mM. The ﬁnal yield of recombinant
ToxB was very low (130 g from 10 liters of culture).
TABLE 1 Antibodies used in this studya
Speciﬁcity Antibody clone Purpose Reference and/or supplier
bo CD3 MM1A FC VMRD
bo CD4* CC30 FC 40
bo CD8* CC63 FC 40
bo WC-1* CC15 FC 41
bo -TCR GB21A FC VMRD
Mouse IgG1 IgG1-FITC FC Invitrogen
Mouse IgG2a IgG2a-PE FC Invitrogen
Mouse IgG2b IgG2b-FITC FC Invitrogen
bo Ig light chain* ILA-58 BI/TI 42
Ovine CD335* (cross-reactive) EC1.1 NKI/TI 30; provided by Timothy Connelly
CD8* ILA-105 TI 43
CD4* ILA-12 TI 44
bo IFN- CC330 ELISA Serotec
bo IFN- CC302b ELISA Serotec
bo IL-4 CC313 ELISA Serotec
bo IL-4 CC314b ELISA Serotec
bo IL-10 CC318 ELISA Serotec
bo IL-10 CC320b ELISA Serotec
bo IL-2 AbD14385 ELISA 37; provided by Martin Vordermeier
bo IL-2 Goat serum-b ELISA R&D Systems
aAsterisks indicate antibodies produced in-house from hybridomas. bo, bovine; Ig, immunoglobulin; b,
biotinylated; FC, ﬂow cytometry; BI, B cell isolation; TI, T cell isolation; NKI, NK cell isolation.
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Isolation of PBMCs from bovine blood. Access to bovine blood for these studies was approved by
the local animal welfare and ethical review body, and blood collection was carried out in accordance with
the Animals (Scientiﬁc Procedures) Act, 1986. Peripheral blood mononuclear cells were isolated from
Holstein-Friesian cattle aged 12 to 18 months old. Brieﬂy, blood was collected into citrate phosphate
dextrose in bags or syringes. Following centrifugation at 1,200	 g for 15 min to generate an initial buffy
coat, the white blood cell fractions were pooled and layered over Ficoll-Paque Plus (GE Healthcare) and
centrifuged for 30 min at 1,200 	 g with the brake off. The PBMCs were collected from the interface and
washed several times before use and then further puriﬁed depending on the cell population of interest.
Cell isolation methods. The T cell fraction was enriched from isolated PBMCs using a sterile wool
column (Polysciences, Inc.), as previously described (5). The B cell fraction was magnetically sorted from
PBMCs using an anti-bovine Ig light chain antibody (28) (Table 1) and magnetically activated cell sorting
(MACS) LS columns (Miltenyi Biotec) by following the manufacturer’s instructions. The purity of cells was
assessed by single-channel ﬂow cytometry and was 95%. The NKp46 (CD335) NK cell fraction was
isolated using magnetic sorting and positive selection from PBMCs as previously published (29), using
antibody EC1.1 (30), and transferred into medium lacking IL-2 overnight. Brieﬂy, cells were seeded at
5 	 105 cells/ml in 24-well tissue culture treated plates in RPMI 1640 medium containing 10% (vol/vol)
fetal bovine serum (FBS), 100 U/ml of penicillin-streptomycin, 2 mM L-glutamine, 0.1 mM nonessential
amino acids, 1 mM sodium pyruvate, and 50 M beta-mercaptoethanol and left overnight at 37°C in a
5% CO2 humidiﬁed atmosphere to allow disassociation of the magnetic beads. Beads and bead-
associated cells were removed using a magnet. The remaining cells were collected, washed, counted,
seeded at 2 	 105 cells/well in 96-well plates, stimulated with bovine IL-12 and -18 (produced in-house
[31]) at concentrations of 20 biological units (BU)/ml and 20 ng/ml, respectively, with and without
lymphostatin, as indicated, and incubated at 37°C in a 5% CO2 atmosphere (32). After 24 h, the cell-free
supernatant was collected from the plates and frozen at 20°C until assayed. The purity of cells was
evaluated by single-channel ﬂow cytometry and was on average 85%.
T and B cell stimulation. Except where indicated, T cells were stimulated with the mitogen
concanavalin A (ConA) at a ﬁnal concentration of 1 g/ml as previously described (5). rLifA was added
at a ﬁnal concentration and time as indicated in the ﬁgure legends in a ﬁnal volume of 100 l/well. Where
cells were pretreated with recombinant protein, cells were spun down and washed twice with
phosphate-buffered saline (PBS) to remove any remaining protein before addition of the stimulant. The
carrier buffer for rLifA was determined to have no effect on ConA stimulation of cells (data not shown).
Where required, phorbol 12-myristate 13-acetate (PMA) and ionomycin were used to treat T cells at 50
ng/ml and 1 g/ml, respectively. For IL-2 stimulation, PBMCs were cultured at 106/ml in medium (Iscove’s
modiﬁed Dulbecco’s medium, 10% [vol/vol] FBS, 50 M beta-mercaptoethanol, 50 g/ml of gentamicin)
for 96 h with 5 g/ml of ConA to upregulate the IL-2 receptor as previously described (33). Cells were
taken up and washed in buffer (Hanks balanced salt solution, 2% [vol/vol] FBS, 10 U/ml of sodium
heparin, 50 g/ml of gentamicin, 0.05% [vol/vol] beta-mercaptoethanol). Cells were then plated in
96-well ﬂat-bottom plates as described above, treated with lymphostatin, and stimulated with tissue
culture supernatant containing recombinant bovine IL-2 (provided by S. Wattegedera, Moredun Research
Institute) for 72 h at 37°C in a 5% CO2 humidiﬁed atmosphere. Measurements of the ConA-stimulated
response were typically 2- to 5-fold higher than for cells alone. B cells were assayed for IL-4-stimulated
proliferation similarly to T cells. Brieﬂy, cells were incubated with a 1/50 dilution of bovine IL-4 containing
tissue culture supernatant (produced in-house and titrated for optimal activity [34]), with and without
recombinant lymphostatin, for a total of 72 h. For all of these assays, at 18 h before the end of incubation,
the colorimetric substrate CellTiter 96 AQueous One (Promega) was added to all wells, and optical
density measurements were subsequently carried out at 492 nm on a Multiskan Ascent plate reader
(Thermo Scientiﬁc). Absorbance readings for IL-4 stimulation were typically more than 2-fold higher than
for cells alone. Cells and medium alone were used as negative controls. Background medium measure-
ments were subtracted from all values. The response of stimulated lymphocytes to treatments is
expressed as a proliferation index, calculated as follows: absorbance (ratio of treatment minus back-
ground)/absorbance (mitogen, antigen, or cytokine alone minus background). For all proliferation
experiments, cells alone with no treatment, cells treated with the stimulus, and cells treated with protein
carrier buffer plus stimulus were included as controls. The ratio of the absorbance readings of stimulus
minus treatment/cells alone was used to verify that each individual assay was successful.
Antigen-speciﬁc stimulation of bovine CD4 and CD8 T cells. A Holstein-Friesian calf was immu-
nized against the protozoan parasite Theileria parva, the causative agent of East Coast fever, by
simultaneous subcutaneous administration of cryopreserved infectious sporozoites and long-acting
oxytetracycline (20 mg/kg) as described elsewhere (17). PBMCs were isolated 6 weeks postimmunization
and were stimulated at 7-day intervals by coculture with a gamma-irradiated (60 Gy) transformed cell line
permanently infected with T. parva. This transformed line was established by in vitro infection of
autologous naive PBMCs with T. parva sporozoites as described elsewhere (35), and such lines express
high levels of major histocompatibility complex class I (MHC-I) and MHC-II and effectively act as
antigen-presenting cells for T. parva antigens. At day 21, CD4- and CD8-positive T cells were puriﬁed by
ﬂuorescence-activated cell sorting (FACSAria III; BD Biosciences) by negative selection using monoclonal
antibodies speciﬁc for -TCR and either anti-CD8 or anti-CD4 (Table 1). Puriﬁed T cell lines were
maintained in culture (supplemented with recombinant human IL-2 [rhIL-2; Proleukin, Novartis] at 100
U/ml) by weekly restimulation with infected cells as described above, at a 1:1 ratio for CD4 T cells and
a 5:1 ratio for CD8 T cells. The purity of T cell lines was assessed by immunoﬂuorescence staining and
ﬂow cytometry (FACS Calibur; BD Biosciences) immediately prior to use, and the lines were conﬁrmed to
be 99% pure CD4 or CD8 T cells.
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IFN- ELISPOT assay. IFN--producing cells were assessed by ELISPOT assay according to the
principles described in reference 36. Brieﬂy, 96-well multiscreen-HA 45-m plates (Merck Millipore) were
coated overnight with 8 g/ml of anti-bovine IFN- capture antibody (Table 1). After washing and
blocking for 2 h with RPMI medium supplemented with 10% (vol/vol) FBS, cells and reagents were set
up. Heterogeneous CD4 or CD8 T cell populations derived from a single donor as described above
were plated on the prepared plates at a density of 105 cells/well at day 7 after treatment with rhIL-2 in
RPMI medium supplemented with 10% heat-inactivated FCS, 100 U/ml of penicillin, 100 g/ml of
streptomycin, 2 mM glutamine, and 50 M 2-mercaptoethanol. Cells were incubated with recombinant
lymphostatin and stimulated with irradiated autologous T. parva-infected cells as antigen-presenting
cells (APCs) at a ratio of 10:1 T cells to irradiated stimulators. Cells were incubated overnight at 37°C in
a 5% CO2 humidiﬁed atmosphere. Plates were incubated for 18 h at 37°C before washing and addition
of 5 g/ml of biotinylated anti-bovine IFN- detection antibody (Table 1). Plates were incubated for 90
min with Vectastain ABC (peroxidase standard; Vector Laboratories), followed by development with
3-amino-9-ethylcarbazole (AEC) substrate solution (Merck Millipore). The reaction was stopped with
copious quantities of water, and plates were dried and then read on an automated plate reader
(Advanced Imaging Devices) using ELISPOT 7.0 Ispot software (Advanced Imaging Devices). Wells with T
cells alone, irradiated stimulators alone, and protein alone were included as negative controls.
Flow cytometry. Cells were stained with antibodies as indicated in Table 1. Where appropriate,
secondary staining with an appropriate antibody-coupled ﬂuorophore was carried out. All samples were
analyzed on a FACSCalibur using CellQuest (BD Biosciences) and FlowJo software (Tree Star). A minimum
of 20,000, and up to 50,000, events were collected with an initial gate for live cells based on forward/side
scatter parameters.
ELISAs. Bovine cytokines were measured using a standard sandwich enzyme-linked immunosorbent
assay (ELISA) technique. The same method was used for IFN-, IL-4, and IL-10. Brieﬂy, 96-well plates
(Immunosorb; Nunc) were coated with capture antibody as indicated in Table 1 and incubated at either
ambient temperature or 4°C overnight. Plates were washed 5 times with wash buffer (PBS–0.05%
[vol/vol] Tween 20) and blocked for 2 h at ambient temperature in PBS containing 1 mg/ml of sodium
casein. Plates were washed 5 times in wash buffer. Supernatants were added either neat (T cell cytokine
secretion) or at an appropriate dilution to fall on the standard curve (NK cells), incubated for 2 h at
ambient temperature, and washed again ﬁve times with wash buffer, and detection antibody was added
at the concentration indicated in Table 1. Plates were incubated for 1 h and washed again ﬁve times in
wash buffer, and streptavidin-horseradish peroxidase (HRP) conjugate was added. Plates were incubated
for 90 min and washed a ﬁnal ﬁve times in wash buffer. Signal was developed using a 3,3=,5,5=-
tetramethylbenzidine (TMB) substrate solution (BioLegend). Optical density measurements were carried
out at 450 nm on a Multiskan Ascent plate reader (Thermo Scientiﬁc). Bovine IL-2 was measured using
a previously published protocol (37), antibody was kindly provided by Martin Vordermeier (Animal &
Plant Health Agency, UK), and bovine IL-17A was measured using a commercially available kit (Kingﬁsher
Biotech).
Statistical analysis. Calculation of the effective dose required to inhibit cell proliferation by 50%
(ED50) was carried out using the drm function in the drc package using R (38). All other statistical
analysis as indicated was carried out using Minitab (39). P values of 0.05 were taken to be
signiﬁcant.
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